| Literature DB >> 32711416 |
Seyed Mohammad Hosseini1, Javad Mohammadiasl1, Abdulhasan Talaiezadeh2,3, Rahim Alidadi1, Mahdi Bijanzadeh1,2.
Abstract
OBJECTIVE: X-ray cross-complementing group 1 (XRCC1) and 8 Oxo guanine DNA-glycosylase 1 (OGG1) genes are implicated in the repair of single-stranded breaks (SSBRs) and base excision repair (BER) pathways. Common polymorphisms in DNA repair genes are supposed to decrease the capability of DNA repair and cause genetic instability. This study was designed to investigate the association between XRCC1 (rs25487) and OGG1 (rs1052133) polymorphisms and susceptibility to colorectal cancer (CRC) in the Ahvaz city, south-west Iran.Entities:
Keywords: Polymorphism; colorectal cancer; restriction fragment length polymorphism
Mesh:
Substances:
Year: 2020 PMID: 32711416 PMCID: PMC7573413 DOI: 10.31557/APJCP.2020.21.7.1919
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Details of PCR and RFLP Procedures and Observed Products
| Genotype | Primers (forward and reverse) | PCR conditions | PCR product | Restriction enzyme | Restriction products |
|---|---|---|---|---|---|
| OGG1 ( | 5-GGAAGGTGCTTGGGAAT-3 | 25 µl of PCR mixture:8ul master mix with 3 µl DNA and 14 µl dw. | 200 bp |
| Ser/Ser: 200 bp |
| XRCC1 | 5-TTGTGCTTTCTCTGTGTCCA-3 | 25 µl of PCR mixture: 8 µl master mix with 3 ul DNA and 14 µl dw. | 615bp |
| Gln / Gln: 375 bp, 240 bp |
1Distilled water
Figure 1Representative Electrophoresis Gels Obtained by PCR-RFLP for the XRCC1 (rs25487) and OGG1 (rs1052133) polymorphisms. M is DNA marker ladder contains a 100 base pair (bp) marker and lane 1 is undigested PCR-amplified product. The left panel is for the XRCC1 (rs25487) polymorphism: lane 2 is genotype AA for Gln / Gln: 375 bp, 240 bp; lane 3 is genotype AG for Arg/Gln: 615 bp, 375 bp, 240 bp and lane 4 is genotype GG for Arg/Arg: 615 bp. The right panel is for the OGG1 (rs1052133) polymorphism: lane 2 is genotype GG for Cys/Cys: 100 bp; lane 3 is genotype CG for Ser/Cys: 100 bp, 200 bp; and lane 4 is genotype CC for Ser/Ser: 200 bp
Comparison of Genotypes and Alleles Frequencies of each Polymorphism between Patients and Controls Groups
| Genotype/Allele | Patients | Controls | OR (95% CI)2 |
| Adjusted3 | |
|---|---|---|---|---|---|---|
| N=150 (%) | N=150 (%) | OR (95% CI) |
| |||
|
| ||||||
| Arg/Arg (GG) | 39 (26.0%) | 52 (34.7%) | 1 (reference) | |||
| Arg/Gln (GA) | 87 (58.0%) | 92 (61.3%) | 1.2 (0.7-2.09) | 0.3 | 1.33 (0.76-2.35) | 0.3 |
| Gln / Gln (AA) | 24 (16.0%) | 6 (4.0%) |
|
|
|
|
| Arg (G) | 135 (45.0%) | 104 (34.7%) | 1 (reference) | |||
| Gln (A) | 165 (55.0%) | 196 (65.3%) |
|
| ||
| AA vs GG+GA | 127 (84.7%) | 144 (96.0%) |
|
|
|
|
|
| ||||||
| Ser/Ser (CC) | 91 (48.9%) | 95 (51.1%) | 1 (reference) | |||
| Ser/Cys (CG) | 57 (51.4%) | 54 (48.6%) | 1.1 (0.6-1.7) | 0.6 | 1.03 (0.7-1.7) | 0.2 |
| Cys/Cys (GG) | 2 (2.2%) | 1 (1.0%) | 2.08 (0.2-23) | 0.5 | 3.08 (0.3-36) | 0.3 |
| Ser (C) | 239 (79.7%) | 244 (81.3%) | 1 (reference) | |||
| Cys (G) | 61 (20.3%) | 56 (18.7%) | 1.09 (0.7-1.6) | 0.6 | ||
2Crude OR; 3Adjusted for gender, age, smoking; Significant values are shown in bold.
Influence of Interaction between Clinical and Demographics Characteristics of CRC and XRCC1 (rs25487) Gene Polymorphism
| Parameters | Patients (number) | controls (number) | OR (CI95%)4 |
| OR(CI95%)5 |
|
|---|---|---|---|---|---|---|
| Gender | ||||||
| Man | 82 | 70 | ||||
| Arg/Arg | 28 | 26 | 1 (reference) | 1 (reference) | ||
| Arg/Gln | 38 | 41 | 1.2 (0.5-2.3) | 0.6 | 0.9 (0.4-2) | 0.9 |
| Gln / Gln | 16 | 3 | 4.9 (1.3-18) | 0.02 | 8.6 (1.7-41) | 0.007 |
| AA vs GG+GA | 66 | 67 | 2.3 (1.2-4.4) | 0.01 | 8.1 (2-32) | 0.003 |
| Woman | 68 | 80 | ||||
| Arg/Arg | 11 | 26 | 1 (reference) | 1 (reference) | ||
| Arg/Gln | 49 | 51 | 0.4 (0.1-0.9) | 0.04 | 2.1 (0.9-4.7) | 0.07 |
| Gln / Gln | 8 | 3 | 6.3 (1.4-28.3) | 0.01 | 6.8 (1.2-36) | 0.02 |
| AA vs GG+GA | 60 | 7 | 1.8 (0.9-3.5) | 0.07 | 3.8 (0.8-17) | 0.07 |
| Smoking | ||||||
| Yes | 40 | 44 | ||||
| Arg/Arg | 9 | 17 | 1 (reference) | 1 (reference) | ||
| Arg/Gln | 16 | 25 | 1.2 (0.4-3.3) | 0.7 | 1.1 (.03-4) | 0.7 |
| Gln / Gln | 15 | 2 |
|
|
|
|
| AA vs GG+GA | 25 | 42 |
|
|
|
|
| No | 110 | 106 | 1 (reference) | 1 (reference) | ||
| Arg/Arg | 30 | 35 | 1.2 (0.6-2.2) | 0.4 | 1.5 (0.8-2.9) | 0.1 |
| Arg/Gln | 71 | 67 | 2.6 (0.7-9.3) | 0.1 | 3.5 (0.8-14.8) | 0.08 |
| Gln / Gln | 9 | 4 | 2.2 (0.6-7.6) | 0.1 | 2.1 (0.6-7.2) | 0.2 |
| AA vs GG+GA | 80 | 71 | 2.2 (0.6-7.6) | 0.1 | 2.1 (0.6-7.4) | 0.2 |
| age | ||||||
| <50 | 49 | 46 | ||||
| Arg/Arg | 15 | 17 | 1 (reference) | 1 (reference) | ||
| Arg/Gln | 27 | 29 | 1.05 (0.4-2.5) | 0.9 | 1.1 (0.3-2.6) | 0.9 |
| Gln / Gln | 7 | 0 | ----------- | ----------- | ||
| AA vs GG+GA | 42 | 46 | ----------- | ----------- | ||
| >50 | 101 | 104 | ||||
| Arg/Arg | 24 | 35 | 1 (reference) | 1 (reference) | ||
| Arg/Gln | 60 | 63 | 1.3 (0.7-2.6) | 0.3 | 1.5 (0.7-3) | 0.2 |
| Gln / Gln | 17 | 6 |
|
|
|
|
| AA vs GG+GA | 84 | 98 |
|
|
|
|
4 Crude OR; 5 Adjusted for gender, age, smoking; Significant values are shown in bold.
Association between XRCC1 Gene Polymorphism and Tomur Characteristics
| Variables | Cases (n=150) | ||
|---|---|---|---|
| Group I | Group II | OR (95% CI); p | |
| Tumor location | Colon = 49 (42.9%) | Rectum = 65 (57.1%) | |
| Arg/Arg; n = 39 | 21 (53.8%) | 18 (46.2%) | 1 (Ref) |
| Arg/Gln; n = 87 | 49 (56.3%) | 38 (43.7%) | 0.9 (0.4–1.9); 0.5 |
| Gln / Gln; n = 24 | 15 (62.5%) | 9 (37.5%) | 0.7(0.2–1.9); 0.7 |
| AA vs GG+GA; n = 126 | 70 (55.6%) | 56 (44.4%) | 0.7 (0.3–1.8); 0.5 |
| Metastasis | Yes = 18 (12%) | No = 132 (88%) | |
| Arg/Arg; n = 39 | 4 (10.3%) | 35 (89.7%) | 1 (Ref) |
| Arg/Gln; n = 87 | 8 (9.2%) | 79 (90.8%) | 1.1 (0.3–3.9); 0.8 |
| Gln / Gln; n = 24 | 6 (25%) | 18 (75%) | 0.3 (0.08–1.3); 0.1 |
| AA vs GG+GA; n = 126 | 12 (9.5%) | 114 (90.5%) |
|
| Stage | I+II = 74 (49.3%) | III+IV = 76 (50.7%) | |
| Arg/Arg; n = 39 | 25 (64.1%) | 14 (35.9%) | 1 (Ref) |
| Arg/Gln; n = 87 | 39 (44.8%) | 48 (55.2%) |
|
| Gln / Gln; n = 24 | 10 (41.7%) | 14 (58.3%) | 2.5 (0.8–7.09); 0.08 |
| AA vs GG+GA; n = 126 | 64 (50.8%) | 62 (49.2%) | 1.4 (0.5–3.4); 0.4 |
Significant values are shown in bold